Research
Hormonal
Dual incretin agonists (GLP-1R/GIPR) such as tirzepatide offer superior weight loss and glycemic control compared to GLP-1 mono-agonists, with a safety profile comparable to mono-agonists.
Tirzepatide, a once-weekly injection targeting both GLP-1 and GIP receptors, has demonstrated significant weight loss (up to 22.5%) and improved blood sugar control in Phase 3 trials. Importantly, its side effect profile is similar to existing GLP-1 drugs, making it a highly effective option for managing obesity and type 2 diabetes.
StrongSupportsVERY_HIGH confidence
In its phase 3 trial in adults with obesity, the highest dose of 15 mg once weekly produced an average reduction in body weight of 22.5% after 72 weeks of treatment [91]... Critically, the most frequent adverse events with tirzepatide, mild to moderate gastrointestinal events... were not higher than semaglutide in SUPRASS-2 [97].
Why this rating
Based on Phase 3 trials, the gold standard for clinical efficacy.
Source
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Robert M. Gutgesell et al. · Diabetes Therapy · 2024
narrative_reviewCited 51×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →